| Date | Time | Source | Announcement |
|---|---|---|---|
| 25 Nov 2015 | 11:56 AM | Holding(s) in Company | |
| 17 Nov 2015 | 03:26 PM | Holding(s) in Company | |
| 17 Nov 2015 | 01:19 PM | Holding(s) in Company | |
| 16 Nov 2015 | 12:47 PM | Holding(s) in Company | |
| 16 Nov 2015 | 07:00 AM | Appointment of Broker | |
| 11 Nov 2015 | 05:15 PM | Holding(s) in Company | |
| 09 Nov 2015 | 07:00 AM | Placing of Shares & admission to Official List LSE |
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.
Hemo share price launched on LSE at 3p in 2017.